ReviewThe Yale journal of biology and medicine2021
Chronic Pulmonary Aspergillosis: A Brief Review.
Review in The Yale journal of biology and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 22 citations in OpenAlex.
- Review
- Impact of surgical margins on treatment outcomes in pulmonary resections forJournal of thoracic disease · 2026Article
- Chronic Pulmonary Aspergillosis in Children: A Scoping Global Review.Open forum infectious diseases · 2026Article
- Performance of the LDBioMicrobiology spectrum · 2026Article
- Multimodal interventional bronchoscopy for chronic pulmonaryFrontiers in medicine · 2026Article
- Pulmonary Aspergillosis Developing After the First Chemotherapy Session in a 15-Year-Old Boy: A Case Report.International medical case reports journal · 2026Article
- Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- Is Pulmonary Mycoses Shadowed by Tuberculosis? Mandate to Hit the Bull's Eye-An Indian Perspective.Pathogens (Basel, Switzerland) · 2025Review
- A retrospective study exploring chronic pulmonary aspergillosis in post-tuberculosis lung disease patients.Journal of thoracic disease · 2025Article
- Chronic pulmonary aspergillosis in tea population of Assam.PLoS neglected tropical diseases · 2025Article
- Efficacy and Safety of Amphotericin B Colloidal Dispersion for Patients with Invasive Fungal Disease and Febrile Neutropenia: A Registry-Based, Multicenter, Retrospective, Real-World Study.Infection and drug resistance · 2025Article
- Efficacy and Safety of Amphotericin B Colloidal Dispersion via Nebulized Inhalation Combined with Intravenous Therapy for Invasive Pulmonary Fungal Disease: A Single-Center, Retrospective Cohort Study.Infection and drug resistance · 2025Article
- Three-Month Mortality in Nonhaematological Patients with Chronic Pulmonary Aspergillosis: Differences between Subtypes.Journal of fungi (Basel, Switzerland) · 2024Article
- Aspergillus hubkae, a Novel Species Isolated from a Patient with Probable Invasive Pulmonary Aspergillosis.Mycopathologia · 2024Article
- Management of Polypharmacy and Potential Drug-Drug Interactions in Patients with Pulmonary Aspergillosis: A 2-Year Study of a Multidisciplinary Outpatient Clinic.Journal of fungi (Basel, Switzerland) · 2024Article
- Chronic pulmonary aspergillosis - a guide for the general physician.Clinical medicine (London, England) · 2024Review
- Social Mycology: Using Social Media Networks in the Management of Aspergillosis and Other Mycoses.Mycopathologia · 2023Review
- Congenital pulmonary airway malformation complicated by aspergilloma: A rare adulthood presentation - Case report.Medical mycology case reports · 2023Article
- Residual respiratory disability after successful treatment of pulmonary tuberculosis: a systematic review and meta-analysis.EClinicalMedicine · 2023Article
- Could the Lung Be a Gateway for Amphotericin B to Attack the Army of Fungi?Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic Pulmonary Aspergillosis (CPA) is a destructive pulmonary disease caused by a fungal infection, affecting mainly individuals with prior or concurrent pulmonary conditions. It has a global prevalence of 42 per 100,000 population, but in the US and Europe, prevalence is less than 1 per 100,000. The clinical definition of CPA is based on various factors accounting for comorbidities, clinical presentation, and duration. It may be categorized into five subtypes that the disease may evolve between over time. Based on global consensus covering the spectrum of low-resource to high-resource settings, diagnosis is a multi-factorial process that involves a combination of clinical presentation persisting over 3 months, radiological findings, positive culture growth, and serological tests. CPA remains underdiagnosed due to a lack of awareness and is often misdiagnosed due to the comorbidities present. Treatment options are limited due to a lack of research. Furthermore, associated comorbidities and drug interactions further complicate treatment plans. Follow-up throughout treatment should be based on understanding the predictors of mortality. Identification of potential relapse or resistance to antifungal therapy is crucial to limit the low long-term survival rate. Awareness surrounding this devastating disease needs to be raised further to enable earlier identification, improve understanding of patient factors associated with prognosis, and the future potential for targeted therapies. This review aims to raise awareness of this rare condition among practitioners, by providing an overview of common risk factors influencing the prevalence and incidence of the disease. We further discuss current approaches and recent advancements in CPA diagnosis and treatment.
Indexed as
Identifiers
34970105PMC8686779W4226439375What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.